TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+11.67%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$688M
AUM Growth
+$688M
(-16%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-19.86%
Top 10 Holdings %
Top 10 Hldgs %
47.84%
Holding
112
New
17
Increased
23
Reduced
33
Closed
23
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$19.3M |
| 2 |
Vaxcyte
PCVX
|
$14.4M |
| 3 |
Moderna
MRNA
|
$14.4M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
$13.1M |
| 5 |
BioAtla
BCAB
|
$9.55M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$42.3M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$21.2M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$20.2M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
$18.1M |
| 5 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$14.9M |
Sector Composition
| 1 | Healthcare | 98.38% |
| 2 | Consumer Discretionary | 0.64% |
| 3 | Communication Services | 0% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$569M
| $81.5M | 11.84% | 2,628,678 | – | – |
|
2
Altimmune
ALT
$338M
| $44.4M | 6.45% | 2,700,450 +100,000 | +4% | +$1.65M |
|
|
BLUE
3
DELISTED
bluebird bio
BLUE
| $32.1M | 4.66% | 4,635,528 -1,700,000 | -27% | -$11.8M |
|
4
Tarsus Pharmaceuticals
TARS
$2.47B
| $29.3M | 4.26% | 2,001,585 -88,271 | -4% | -$1.29M |
|
|
5
BioAtla
BCAB
$26.7M
| $25.8M | 3.74% | 3,124,076 +1,157,025 | +59% | +$9.55M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $25M | 3.63% | 105,000 +5,000 | +5% | +$1.19M |
|
|
7
Axsome Therapeutics
AXSM
$6.05B
| $24.7M | 3.59% | 320,000 +250,000 | +357% | +$19.3M |
|
8
Immunocore
IMCR
$1.62B
| $23.1M | 3.36% | 405,600 | – | – |
|
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $21.8M | 3.17% | 1,120,000 +670,000 | +149% | +$13.1M |
|
10
KalVista Pharmaceuticals
KALV
$678M
| $21.6M | 3.14% | 3,196,446 +1,396,446 | +78% | +$9.44M |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $20.2M | 2.94% | 692,925 -190,000 | -22% | -$5.55M |
|
|
ONC
12
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $18.7M | 2.72% | 85,000 -20,000 | -19% | -$4.4M |
|
13
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.6M | 2.42% | 1,450,000 +250,000 | +21% | +$2.87M |
|
14
Harmony Biosciences
HRMY
$2.12B
| $15.5M | 2.25% | 281,200 -28,800 | -9% | -$1.59M |
|
|
15
Vaxcyte
PCVX
$4B
| $14.4M | 2.09% | +300,000 | New | +$14.4M |
|
|
16
Moderna
MRNA
$9.37B
| $14.4M | 2.09% | +80,000 | New | +$14.4M |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.7M | 1.85% | 240,000 -400,000 | -63% | -$21.2M |
|
18
AstraZeneca
AZN
$248B
| $11.5M | 1.67% | 170,000 +20,000 | +13% | +$1.36M |
|
19
Nkarta
NKTX
$151M
| $11.2M | 1.63% | 1,870,000 +1,207,128 | +182% | +$7.23M |
|
20
Heron Therapeutics
HRTX
$207M
| $9.39M | 1.36% | 3,755,934 -3,084,066 | -45% | -$7.71M |
|
21
Enanta Pharmaceuticals
ENTA
$180M
| $9.3M | 1.35% | 200,000 +62,300 | +45% | +$2.9M |
|
22
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $8.99M | 1.31% | 600,000 | – | – |
|
|
ALBO
23
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $8.9M | 1.29% | 411,968 -687,548 | -63% | -$14.9M |
|
|
24
Bio-Rad Laboratories Class A
BIO
$8.06B
| $8.83M | 1.28% | 21,000 -43,000 | -67% | -$18.1M |
|
25
Cullinan Oncology
CGEM
$445M
| $8.54M | 1.24% | 809,231 +185,215 | +30% | +$1.95M |
|